23:41 , May 3, 2017 |  BC Extra  |  Company News

Management tracks

Immunotherapy company GammaDelta Therapeutics Ltd. (London, U.K.) named Paolo Paoletti CEO, Natalie Mount CSO, and Dayle Hogg COO. Paoletti and Hogg both joined GammaDelta from Kesios Therapeutics Ltd. (London, U.K.), where Paoletti was CEO and...
00:35 , Mar 10, 2017 |  BC Week In Review  |  Clinical News

AC-1204: Ph III NOURISH AD data

Top-line data from the double-blind, U.S. Phase III NOURISH AD trial in about 418 non-carriers of apolipoprotein E (APOE) epsilon 4 (APOE4) with mild to moderate AD showed that once-daily 40 g oral AC-1204 missed...
02:31 , Mar 4, 2017 |  BioCentury  |  Product Development

Diagnosing AD trials

A battery of expensive late-stage failures has made it obvious to Alzheimer’s disease companies that more and better diagnostics will be essential to get new disease-modifying therapies to patients. But so far, the approaches being...
20:14 , Feb 28, 2017 |  BC Extra  |  Clinical News

Accera attributes Phase III AD failure to bioavailability issue

Accera Inc. (Boulder, Colo.) said AC-1204 missed the primary endpoint in the Phase III NOURISH AD trial to treat mild to moderate Alzheimer's disease. Compared with placebo, the candidate failed to significantly improve AD Assessment...
07:00 , Aug 8, 2016 |  BC Extra  |  Company News

Management tracks

Suneva Medical Inc. (San Diego, Calif.) said chairman and CEO Nicholas Teti resigned. The dermatology company promoted Preston Romm to president and CEO from COO. Synthetic biology company Intrexon Corp. (NYSE:XON) hired Andrew Last as...
07:00 , May 23, 2016 |  BC Week In Review  |  Clinical News

AC-1204: Completed Phase III enrollment

Accera completed enrollment of >400 patients with mild to moderate AD in the double-blind, placebo-controlled, U.S. Phase III NOURISH AD trial evaluating once-daily oral AC-1204 for 26 weeks. NOURISH AD includes a 26-week open-label extension....
00:22 , Jun 3, 2015 |  BC Extra  |  Company News

Management tracks

Neurology play Pozen Inc. (NASDAQ:POZN) named Adrian Adams CEO, replacing retiring Chairman, President and CEO John Plachetka. Adams was CEO of Auxilium Pharmaceuticals Inc. , which Endo International plc (NASDAQ:ENDP; TSX:ENL) acquired. Cancer company Ziopharm...
07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Acetyl-coenzyme A carboxylase-b (ACACB; ACC2) Mouse studies suggest inhibiting ACC2 could help treat or prevent metabolic diseases. In mice fed a high-fat...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

Accera management update

Accera Inc. , Broomfield, Colo.   Business: Neurology   Hired: Thomas Werner, a director, as president and CEO  ...
08:00 , Feb 18, 2010 |  BC Innovations  |  Targets & Mechanisms

Turning up the heat on HD

Researchers at Duke University have found small molecules that help cells untangle aggregates of the misfolded protein thought to cause Huntington's disease. 1 The molecules are now the lead compounds for Chaperone Therapeutics Inc. ,...